Christopher S. Esslinger

Affiliations: 
Neuroscience University of Montana, Missoula, MT 
Area:
Pharmacology, Organic Chemistry
Google:
"Christopher Esslinger"
Mean distance: 35622
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Esslinger CS, Agarwal S, Gerdes J, et al. (2005) The substituted aspartate analogue L-beta-threo-benzyl-aspartate preferentially inhibits the neuronal excitatory amino acid transporter EAAT3. Neuropharmacology. 49: 850-61
Bridges RJ, Esslinger CS. (2005) The excitatory amino acid transporters: pharmacological insights on substrate and inhibitor specificity of the EAAT subtypes. Pharmacology & Therapeutics. 107: 271-85
Esslinger CS, Cybulski KA, Rhoderick JF. (2005) Ngamma-aryl glutamine analogues as probes of the ASCT2 neutral amino acid transporter binding site. Bioorganic & Medicinal Chemistry. 13: 1111-8
Carrigan CN, Bartlett RD, Esslinger CS, et al. (2002) Synthesis and in vitro pharmacology of substituted quinoline-2,4-dicarboxylic acids as inhibitors of vesicular glutamate transport. Journal of Medicinal Chemistry. 45: 2260-76
Koch HP, Kavanaugh MP, Esslinger CS, et al. (1999) Differentiation of substrate and nonsubstrate inhibitors of the high-affinity, sodium-dependent glutamate transporters. Molecular Pharmacology. 56: 1095-104
Carrigan CN, Esslinger CS, Bartlett RD, et al. (1999) Quinoline-2,4-dicarboxylic acids: synthesis and evaluation as inhibitors of the glutamate vesicular transport system. Bioorganic & Medicinal Chemistry Letters. 9: 2607-12
Esslinger CS, Koch HP, Kavanaugh MP, et al. (1998) Structural determinants of substrates and inhibitors: probing glutamate transporters with 2,4-methanopyrrolidine-2,4-dicarboxylate. Bioorganic & Medicinal Chemistry Letters. 8: 3101-6
Bartlett RD, Esslinger CS, Thompson CM, et al. (1998) Substituted quinolines as inhibitors of L-glutamate transport into synaptic vesicles. Neuropharmacology. 37: 839-46
See more...